Sangamo Therapeutics Inc (SGMO)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.07+4.22%
Close 2026-07-28 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put SGMO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar broken — Revenue stabilizes near $110M in 2026: FY26 guidance low $100M vs target ~$110M.
View ThesisRevenue is contracting — down about 46% over the past year.
View GrowthManagement screens weak on capital allocation, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 0% on a typical day and fell roughly 70% in its worst 12-month stretch.
View RiskSGMO's revenue must stabilize near $110M to justify its current valuation. Recent guidance suggests FY26 revenue may fall below $100M, indicating a significant shortfall. Revenue growth has been weak, and the latest performance sits below its industry peers. SGMO trades at a valuation below typical for its sector, reflecting skepticism about its growth potential. If SGMO cuts guidance on the next call, it could lead to further declines. The thesis has broken due to the primary pillar of revenue stability failing. This read is provisional.
Trailing returns as of 2026-07-28. SGMO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering SGMO (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SGMO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SGMO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SGMO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-28. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.